RxDoctor Payments Data

John Lanham, MD

Family Medicine · Charlottesville, VANPI 1790746139

Payments from drug & device makers

$1,288in general payments, 2019–2025

Across 39 payments — averaging $33.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$289
  • Pfizer$229
  • AstraZeneca$223
  • Johnson & Johnson$139
  • Biohaven Pharmaceutical Holding Company Ltd.$104
  • Novo Nordisk$102
  • plus $205 from 6 others

What the payments were for

  • Food & beverage$1,288100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,288 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$91,363
Medicare patients
188
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$47,366
Breo ElliptaFluticasone/Vilanterol26$10,587
Tiotropium Bromide11$5,461
PremproEstrogen,con/M-Progest Acet13$3,287
Qvar RedihalerBeclomethasone Dipropionate16$3,106
SymbicortBudesonide/Formoterol Fumarate13$2,684
Rosuvastatin Calcium114$1,900
Lisinopril207$1,811
Amlodipine Besylate214$1,638
Albuterol Sulfate HfaAlbuterol Sulfate43$1,538
Potassium Chloride36$1,242
Atorvastatin Calcium146$1,135
Metformin Hcl92$935
Losartan Potassium64$926
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide12$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro$229$50,65360 claims
AstraZenecaSymbicort$223$2,68413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →